Document
IPR2017-01912, No. 2093-207 Exhibit - Remingtons Ch 89 (P.T.A.B. Nov. 16, 2017)
Cite Document
IPR2017-01912, No. 2093-207 Exhibit - Remingtons Ch 89 (P.T.A.B. Nov. 16, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1086-86 Exhibit - Wilkinson, Tamoxifen Nolvadex Therapy Rationale for Loading Dose Followed by Maintenance Dose for Patients with Metastatic Breast Cancer, 10 CANCE...
Cite Document
IPR2017-01912, No. 1086-86 Exhibit - Wilkinson, Tamoxifen Nolvadex Therapy Rationale for Loading Dose Followed by Maintenance Dose for Patients with Metastatic Breast Cancer, 10 CANCER CHEMOTHERAPY
+ More Snippets
Document
IPR2017-01912, No. 2106-220 Exhibit - Ansel Ch 14 (P.T.A.B. Nov. 16, 2017)
Cite Document
IPR2017-01912, No. 2106-220 Exhibit - Ansel Ch 14 (P.T.A.B. Nov. 16, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1049-49 Exhibit - Anderson, Models of New Antioestrogen Action in Vivo Primary Tumours, 5 THE BREAST 186 91 1996 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01912, No. 1049-49 Exhibit - Anderson, Models of New Antioestrogen Action in Vivo Primary Tumours, 5 THE BREAST 186 91 1996 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1046-46 Exhibit - Prosecution History for the US Patent No 7,456,160 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01912, No. 1046-46 Exhibit - Prosecution History for the US Patent No 7,456,160 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01912, No. 2037-151 Exhibit - Hortobagyi 1997 (P.T.A.B. Nov. 16, 2017)
Cite Document
IPR2017-01912, No. 2037-151 Exhibit - Hortobagyi 1997 (P.T.A.B. Nov. 16, 2017)
+ More Snippets
Document
IPR2017-01912, No. 2168-282 Exhibit - DAgostino 1990 (P.T.A.B. Nov. 16, 2017)
Cite Document
IPR2017-01912, No. 2168-282 Exhibit - DAgostino 1990 (P.T.A.B. Nov. 16, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1075-75 Exhibit - Robertson, JFR et al, A Partially Blind, Randomised, Multicentre Study Comparing the Anti Tumor Effects of Single Doses 50, 125, 250 mg Of Long Acting L...
Cite Document
IPR2017-01912, No. 1075-75 Exhibit - Robertson, JFR et al, A Partially Blind, Randomised, Multicentre Study Comparing the Anti Tumor Effects of Single Doses 50, 125, 250 mg Of Long Acting LA Faslodex
+ More Snippets
Document
IPR2017-01912, No. 2107-221 Exhibit - Avis Ch 2 (P.T.A.B. Nov. 16, 2017)
Cite Document
IPR2017-01912, No. 2107-221 Exhibit - Avis Ch 2 (P.T.A.B. Nov. 16, 2017)
+ More Snippets
Document
IPR2017-01912, No. 2054-168 Exhibit - Beyea 1996 (P.T.A.B. Nov. 16, 2017)
Cite Document
IPR2017-01912, No. 2054-168 Exhibit - Beyea 1996 (P.T.A.B. Nov. 16, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1088-88 Exhibit - Wunsche, Estrogenic Regulation of Clusterin mRNA in Normal and Malignant Endometrial Tissue, 76 INT J CANCER 684 88 1998 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01912, No. 1088-88 Exhibit - Wunsche, Estrogenic Regulation of Clusterin mRNA in Normal and Malignant Endometrial Tissue, 76 INT J CANCER 684 88 1998 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1110-110 Exhibit - Ting, Solubility of Naproxen in Supercritical Carbon Dioxide with and without Cosolvents, 32 IND ENG CHEM RES 1471 81 1993 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01912, No. 1110-110 Exhibit - Ting, Solubility of Naproxen in Supercritical Carbon Dioxide with and without Cosolvents, 32 IND ENG CHEM RES 1471 81 1993 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1058-58 Exhibit - Wakeling, The Future of New Pure Antioestrogens in Clinical Breast Cancer, 25 BREAST CANCER RESEARCH TREATMENT 1 9 1993 (P.T.A.B. Aug. 4, 20...
Cite Document
IPR2017-01912, No. 1058-58 Exhibit - Wakeling, The Future of New Pure Antioestrogens in Clinical Breast Cancer, 25 BREAST CANCER RESEARCH TREATMENT 1 9 1993 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01912, No. 1101-101 Exhibit - Way, Cosolvent Use in Injectable Formulations, Injectable Drug Development Techniques to Reduce Pain and Irritation 215 66 Gupta ed, 1999 (P.T.A.B. A...
Cite Document
IPR2017-01912, No. 1101-101 Exhibit - Way, Cosolvent Use in Injectable Formulations, Injectable Drug Development Techniques to Reduce Pain and Irritation 215 66 Gupta ed, 1999 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01912, No. 2032-146 Exhibit - Labrie 2004 (P.T.A.B. Nov. 16, 2017)
Cite Document
IPR2017-01912, No. 2032-146 Exhibit - Labrie 2004 (P.T.A.B. Nov. 16, 2017)
+ More Snippets